A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

被引：0
|
作者：
Hurvitz, S. A. [1 ]
Galsky, M. D. [2 ]
Shahidi, J. [3 ]
Zhang, G. [4 ]
Raza, S. [3 ]
Necchi, A. [5 ]
机构：
[1] UCLA Med Ctr, Dept Med, Los Angeles, CA USA
[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[3] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
370TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)
    Krop, Ian E.
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Modi, Shanu
    CANCER RESEARCH, 2020, 80 (04)
  • [42] DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody.
    Iwata, Tomomi Nakayama
    Ishii, Chiaki
    Ogitani, Yusuke
    Wada, Teiji
    Agatsuma, Toshinori
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    Sheng, Xinan
    Yan, Xieqiao
    Wang, Lin
    Shi, Yanxia
    Yao, Xin
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    He, Zhisong
    Yu, Guohua
    Ying, Jianming
    Han, Weiqing
    Hu, Changlu
    Ling, Yun
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Fang, Jianmin
    Zhou, Aiping
    Guo, Jun
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 43 - 51
  • [44] A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation
    Lee, Elizabeth K.
    Hendrickson, Andrea E. Wahner
    Colon-Otero, Gerardo
    Pickett, Cheryl A.
    Xiong, Niya
    Cheng, Su-Chun
    Polak, Madeline
    Sawyer, Hannah
    Hayes, Martin
    Matulonis, Ursula A.
    Shapiro, Geoffrey I.
    Konstantinopoulos, Panagiotis A.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [45] POPULATION PHARMACOKINETIC ANALYSIS OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH HER2-POSITIVE BREAST CANCER OR OTHER SOLID TUMORS.
    Yin, O.
    Xiong, Y.
    Endo, S.
    Yoshihara, K.
    AbuTarif, M.
    Wada, R.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S48 - S48
  • [46] A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer
    Planchard, D.
    Li, B. T.
    Murakami, H.
    Shiga, R.
    Lee, C. C.
    Wang, K.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
    Doi, Toshihiko
    Shitara, Kohei
    Naito, Yoichi
    Shimomura, Akihiko
    Fujiwara, Yasuhiro
    Yonemori, Kan
    Shimizu, Chikako
    Shimoi, Tatsunori
    Kuboki, Yasutoshi
    Matsubara, Nobuaki
    Kitano, Atsuko
    Jikoh, Takahiro
    Lee, Caleb
    Fujisaki, Yoshihiko
    Ogitani, Yusuke
    Yver, Antoine
    Tamura, Kenji
    LANCET ONCOLOGY, 2017, 18 (11): : 1512 - 1522
  • [48] EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE JUSTIFICATION OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN HER2-POSITIVE BREAST CANCER PATIENTS.
    Yin, O.
    Wada, R.
    Kastrissios, H.
    AbuTarif, M.
    Garimella, T.
    Lee, C.
    Zhang, L.
    Shahidi, J.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S48 - S48
  • [49] A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, F.
    Anoka, C.
    Dobrowolska, A.
    Chaudhry, A.
    Rowbottom, J.
    Gustavson, M.
    Puvvada, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1253 - S1254
  • [50] EXPOSURE-RESPONSE ANALYSES TO SUPPORT DOSE JUSTIFICATION OF DS-8201A, A HER2-TARGETING ANTIBODY-DRUG CONJUGATE, IN HER2-POSITIVE BREAST CANCER PATIENTS.
    Yin, O.
    Wada, R.
    Kastrissios, H.
    AbuTarif, M.
    Garimella, T.
    Lee, C.
    Zhang, L.
    Shahidi, J.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S41 - S41
12345